AICDA and melanoma: Since these findings suggested that AID mutations inducing ICN as a possible explanation of ICI response, we next analyzed a cohort of 68 melanoma patients treated with anti-PD-1 (Nivolumab) from which WES, neoepitopes, and RNA-seq data were available prior treatment (pre) or 4 weeks after initiation of Nivo (on)34.